Glykeminen L-Glutamiini

LÄHDE

PLoS One. 2014 Nov 20;9(11):e113366. doi: 10.1371/journal.pone.0113366. eCollection 2014.

Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.

Samocha-Bonet D¹, Chisholm DJ¹, Gribble FM², Coster AC³, Carpenter KH⁴, Jones GR⁵, Holst JJ⁶, Greenfield JR⁷.

Author information

Abstract

BACKGROUND AND AIMS:

L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.

CONCLUSIONS:

Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.

TRIAL REGISTRATION:

ClincalTrials.gov NCT00673894.